Aurobindo Pharma Ltd 2020 AR2
The report highlights Aurobindo Pharma Limited's performance for the fiscal year 2019-20, during which the company consolidated its capabilities and expanded its global footprint. The company achieved a revenue growth of 18.1% to ₹230,985 million, with international sales contributing 92% of total revenues. Key milestones included the integration of Apotex's European businesses, the acquisition of R&D assets from Profectus BioSciences, and the completion of clinical trials for its first metered-dose inhaler. On the sustainability front, the company invested ₹486 million in CSR activities, impacting over 600,000 lives, and implemented 137 energy conservation projects that reduced carbon emissions by approximately 13,600 tonnes of CO2e.
Company: Aurobindo Pharma Ltd
Sector: Manufacturing
Country: India
Year: 2020
Type: AR2
Pages: 296
Aurobindo Pharma Ltd
The report highlights Aurobindo Pharma Limited's performance for the fiscal year 2019-20, during which the company consolidated its capabilities and expanded its global footprint. The company achieved a revenue growth of 18.1% to ₹230,985 million, with international sales contributing 92% of total revenues. Key milestones included the integration of Apotex's European businesses, the acquisition of R&D assets from Profectus BioSciences, and the completion of clinical trials for its first metered-dose inhaler. On the sustainability front, the company invested ₹486 million in CSR activities, impacting over 600,000 lives, and implemented 137 energy conservation projects that reduced carbon emissions by approximately 13,600 tonnes of CO2e.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees